Carregant...

Gap Junction Enhancer Increases Efficacy of Cisplatin to Attenuate Mammary Tumor Growth

Cisplatin treatment has an overall 19% response rate in animal models with malignant tumors. Increasing gap junction activity in tumor cells provides the targets to enhance antineoplastic therapies. Previously, a new class of substituted quinolines (PQs) acts as gap junction enhancer, ability to inc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Shishido, Stephanie N., Nguyen, Thu A.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3441663/
https://ncbi.nlm.nih.gov/pubmed/23028705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044963
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!